Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ:AMGN)

274.94 -16.14 (-5.55%)
Streaming Delayed Price Updated: 11:37 AM EDT, Apr 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
52 53 Next >
7 Dow Stocks to Buy on the Dip: March 2024
Analysts expect that the market may be heading toward a correction. These are seven of the best Dow stocks to buy when prices pull back. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich
Some of the market’s favorite biotech stocks have created immense wealth, as evidenced with the recent weight-loss drug stock boom. 
Via InvestorPlace
Buffett’s Backdoor Buys: 3 Stocks His Secret Portfolio Is Quietly Accumulating
Warren Buffett stocks and Berkshire Hathaway's portfolio of companies are hidden investment vehicles hiding in plain sight. 
Via InvestorPlace
Hot Stocks: The 3 Best Opportunities for Investing in Biotech
Biotech stocks can offer some of the best risk vs. reward payoff in the stock market. These three are ones to buy now. 
Via InvestorPlace
Is Amgen Stock a Buy Now?
There are some worrying signs. 
Via The Motley Fool
Looking At Amgen's Recent Unusual Options Activity
Via Benzinga
(AMGN) - Analyzing Amgen's Short Interest
Via Benzinga
Amgen Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
Hot Stocks: The 3 Best Opportunities for Investing in the Dow
Although these Dow stocks are mature enterprises, they still have enough in the tank to pull off some surprises. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
4 Oversold Large Cap Stocks Yielding High Dividends
Overlooked, oversold large-cap stocks offer compelling dividend yields for investors seeking income and potential capital appreciation 
Via MarketBeat
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Interest Rates
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
The Dow’s Best Friends: 3 ‘Dogs’ Ready to Fetch Huge Returns
The Dogs of the Dow strategy is one of the best yearly strategies investors should use to make some good money. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
Obesity Drugs 2024: The Skinny on the Top 3 Weight-Loss Stocks
With therapeutics focused on slimming down skyrocketing, it’s time to consider these top weight-loss stocks. 
Via InvestorPlace
The AI Race Gets Litigious
We've also got a look at the role of patents in pharmaceuticals and the "patent cliff" looming over the next decade. 
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
9 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Medicare's Ambitious Drug Price Negotiation Plan: President Joe Biden Calls To Expand Targeted Medicines To 50 Annually by 2029
Explore President Biden's plan to expand Medicare drug negotiations, targeting at least 50 drugs annually. Uncover the impact on pharmaceutical profits and the broader health-care policy proposals,... 
Via Benzinga
Is It Time to Buy February's 3 Worst-Performing Dow Jones Stocks?
It's only a bargain price if it's actually worth owning. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
It’s Time! 3 Dodgy Pharma Stocks to Sell in February
Explore pharma stocks to sell in February: Eli Lilly, Amgen, BioNTech face overvaluation, volatility, urging investor action. 
Via InvestorPlace
After Soaring 222% in 1 Day, Is Janux Therapeutics Stock a Buy?
The biotech tantalized investors with a very promising data update. 
Via The Motley Fool
Eli Lilly Stock And The Road To 1,000: Weight-Loss Drugs Could Generate $81 Billion
Wall Street isn't properly taking into account Lilly's next-generation drugs, an analyst says. 
Via Investor's Business Daily
Apple Sinks After Wall Street Titan Pulls Magnificent 7 Stock From Conviction List
Goldman Sachs is removing Apple from its Conviction List of buy-rated stocks. Looking at the potential reasons why and who replaced the tech giant. 
Via Benzinga
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
2 Stocks That Could Turn $1,000 Into $2,500 in 5 Years
It will take a lot, but this goal isn't out of reach for these stocks. 
Via The Motley Fool
Better Dividend Growth Stock: AbbVie or Amgen?
A strong case can be made for owning both of these dividend growth stocks. But one of them is the better buy. 
Via The Motley Fool
Amazon Stock: Why it's Finally Included in the Dow Index
Amazon replaced Walgreens in the Dow. While a positive move for Amazon, any impact on the stock's price may be limited due to low index weighting. 
Via MarketBeat
Topics Economy Stocks
Exposures Economy US Equities
Amgen's Upcoming Catalysts In 2024 Set To Unlock Multi-Billion Dollar Markets, Says Goldman Sachs
Amgen's growth outlook in 2024, with updates on key programs and upcoming catalysts. Goldman Sachs sees significant opportunities despite exclusivity losses. Dive into potential market moves and... 
Via Benzinga
3 Biotech Stocks to Buy and Hold for the Next 10 Years
There's a lot to like about these three drugmakers right now, and that shouldn't stop anytime soon. 
Via The Motley Fool
Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On.
Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy. 
Via Investor's Business Daily
3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024
With new innovation and high demand, biotech stocks could offer some of the most explosive opportunities of the year. 
Via InvestorPlace
< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
52 53 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.